Mega Ezetimibe Tablet 10 mg (Ezetimibe)
Ezetimibe 10mg
Tablet · Prescription medication
L&C Bio Co., Ltd.
MFDS item code 202000591 · Approved 2020.02.04
This product's status changed to Approval withdrawn on 2024.07.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of hypercholesterolemia, mixed hyperlipidemia, and homozygous sitosterolemia
This drug is used to reduce elevated total cholesterol and LDL cholesterol in patients with primary hypercholesterolemia and mixed hyperlipidemia. Particularly, it is administered alone or in conjunction with other lipid-lowering agents to enhance effect alongside diet. In patients with homozygous familial hypercholesterolemia, it is used as an adjunct to other therapies, sometimes alone or in combination with statins. It is also utilized to lower plant sterols (sitosterol, campesterol) in patients with homozygous sitosterolemia. Before administering this medication, it is important to assess and treat other underlying conditions and evaluate treatment effectiveness through lipid tests. This drug management helps in reducing the risk of cardiovascular disease and improving lipid status.
Continue a standard cholesterol-lowering diet during treatment with this drug. The recommended dose of this drug is 10 mg once daily, regardless of meals. When administered in combination with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), initiate combination treatment with this drug at the recommended starting dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this drug in combination while maintaining the dose of the HMG-CoA reductase inhibitor. When this drug is administered in combination with fenofibrate (in patients with mixed dyslipidemia), administer it with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use 4. General Precautions). Administration to patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment, but administration of this drug is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use 2. Patients Requiring Caution). Administration to patients with renal impairment No dose adjustment is necessary in patients with renal impairment. Administration to elderly patients No dose adjustment is necessary when administering to elderly patients. Concomitant administration with bile acid sequestrants Administer this drug at least 2 hours before or 4 hours after a bile acid sequestrant (see Precautions for Use 5. Interactions).
This drug should not be used in patients with hypersensitivity to specific components. Patients with active liver disease or persistently elevated liver enzymes in blood tests should avoid combination therapy with this drug and other specific lipid-lowering agents. The use of this drug and specific lipid-lowering agents is prohibited in pregnant or nursing women, so women of childbearing potential should take caution. The use of this drug is not recommended in patients with moderate to severe liver dysfunction. Although this drug is generally safe, side effects such as headache, abdominal pain, diarrhea, fatigue, and muscle pain may occur; therefore, medical consultation should be sought in case of abnormal symptoms. If symptoms such as muscle pain or weakness occur, medical personnel should be informed immediately, and discontinuation of therapy may be necessary. Patients with severe kidney impairment should also take caution, and renal function should be regularly monitored during administration. This drug may interact with other medications, so it is essential to inform the doctor or pharmacist of any ongoing medications. Pregnant or nursing mothers should carefully consider the potential risks and benefits of using this drug. It is recommended for use in children aged 6 years and older, and it is best not to use it in children under 6 years. Elderly patients can use it safely, but some elderly individuals may be more sensitive to the drug, requiring caution. No specific treatment is available for overdose, but appropriate treatment should be provided based on symptoms. This drug should be kept out of the reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This drug is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, to maintain the drug's effectiveness, it is best to store it at room temperature between 1 and 30 degrees Celsius.
White to off-white oblong tablet
10 tablets/box [10 tablets/PTP X 1], 30 tablets/box [10 tablets/PTP X 3], 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ezetimibe 10mg
Tablet · Prescription medication
L&C Bio Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Korea Organon Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Shin Il Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Korea Hutech Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Hwanin Pharmaceutical Co., Ltd.

Ezetimibe 10mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.